Herpes News and Research

RSS

Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.

Having vaccine after shingles appear do not reduce the risk of stroke

Stroke risk increased significantly in the days, weeks and months after shingles appeared, despite use of the shingles vaccine and antiviral therapy to treat it, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.

30 Jan 2019

Injection of genetically modified virus effectively treats metastatic melanoma patients

Injection of a genetically modified virus that induces the body's own immune cells to attack metastatic melanoma effectively treated almost 40 percent of patients with tumors that could not be surgically removed, according to researchers from three prominent cancer centers in a study published as an "article in press" on the Journal of the American College of Surgeons website in advance of print publication.

28 Jan 2019

CMV vaccine provides a new way to fight malaria

Early research on a new approach to protecting against malaria is offering promising, potentially long-lasting results against the persistent parasite that sickens hundreds of millions people each year.

24 Jan 2019

FDA grants clearance to Hologic’s assay for detection of common sexually transmitted infections

Hologic, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for its Aptima Mycoplasma genitalium assay, the first and only FDA-cleared test to detect this under-recognized but increasingly common sexually transmitted infection (STI).

23 Jan 2019

Study shows how herpes viruses and tumors have learned to manipulate the same ancient RNA

Herpes viral infections use the ancient genetic material found in the human genome to proliferate, mimicking the same process tumors have been found to manipulate, Mount Sinai researchers have shown for the first time.

14 Jan 2019

Schizophrenia patients have higher levels of antibodies against Epstein-Barr virus, study shows

New research from Johns Hopkins Medicine and Sheppard Pratt Health System shows that people in the study with schizophrenia also have higher levels of antibodies against the Epstein-Barr virus (EBV), a herpes virus that causes infectious mononucleosis, so-called mono.

9 Jan 2019

Sexual function in women with vulva pain improved with oral nerve pain medication

Women with chronic pain or discomfort around the vulva showed improved sexual function with an oral nerve pain medication used to treat pain caused by a previous herpes infection as well as fibromyalgia, according to a Rutgers study.

2 Jan 2019

Quidel receives CE mark to use Sofia 2 Lyme+ Fluorescent Immunoassay with Sofia 2 analyzer

Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received CE Mark to market Quidel's Sofia 2 Lyme+ FIA to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi, Borrelia garinii, and Borrelia afzelii from serum and plasma specimens.

19 Dec 2018

Cancer patients have greater risk of developing shingles, study shows

People newly diagnosed with cancer, particularly blood cancers, and those treated with chemotherapy have a greater risk of developing shingles, according to a new study in the Journal of Infectious Diseases.

13 Dec 2018

New research explains how large virus shells are formed

A virus, the simplest physical object in biology, consists of a protein shell called the capsid, which protects its nucleic acid genome -- RNA or DNA. The capsid can be cylindrical or conical in shape, but more commonly it assumes an icosahedral structure, like a soccer ball.

5 Nov 2018

Newer vaccine far more successful in preventing shingles, systematic review reveals

A systematic review of clinical studies involving more than two million patients aged 50 years and older suggests a recently released shingles vaccine was far more successful in preventing the painful condition compared to the older vaccine - but also carried greater risk of side-effects.

26 Oct 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Could we prevent Alzheimer's disease by treating herpes?

An exciting new paper suggests that over half of all cases of Alzheimer’s disease could be traced back to herpes simplex virus 1, which causes cold sores.

19 Oct 2018

Survey results highlight the need for better communication between patients and HCPs about bacterial vaginosis

According to an online survey, although healthcare providers report sharing crucial information on bacterial vaginosis with patients, the associated risks of the condition remain a mystery to many women, indicating a significant disconnect.

16 Oct 2018

Researchers develop new techniques for faster detection of Lyme disease bacteria

Researchers have developed techniques to detect Lyme disease bacteria weeks sooner than current tests, allowing patients to start treatment earlier.

11 Oct 2018

Virginia Tech researcher receives $1.7 million to study herpes simplex virus

The National Institute of Neurological Disorders and Stroke of the National Institutes of Health has awarded Andrea Bertke, an assistant professor of infectious diseases in the Department of Population Health Sciences in the Virginia-Maryland College of Veterinary Medicine at Virginia Tech, $1.7 million to study the neuron-specific regulation of herpes simplex viruses 1 and 2.

11 Oct 2018

Researchers develop cancer vaccine platform to improve efficacy of oncolytic enveloped viruses

Researchers at the Faculty of Pharmacy have developed PeptiENV, a cancer vaccine platform, which can be used to improve the therapeutic efficacy of oncolytic enveloped viruses currently in clinical use.

6 Oct 2018

Herpes News and Research

Further Reading

Having vaccine after shingles appear do not reduce the risk of stroke

Injection of genetically modified virus effectively treats metastatic melanoma patients

CMV vaccine provides a new way to fight malaria

FDA grants clearance to Hologic’s assay for detection of common sexually transmitted infections

Study shows how herpes viruses and tumors have learned to manipulate the same ancient RNA

Schizophrenia patients have higher levels of antibodies against Epstein-Barr virus, study shows

Sexual function in women with vulva pain improved with oral nerve pain medication

Quidel receives CE mark to use Sofia 2 Lyme+ Fluorescent Immunoassay with Sofia 2 analyzer

Cancer patients have greater risk of developing shingles, study shows

New research explains how large virus shells are formed

Newer vaccine far more successful in preventing shingles, systematic review reveals

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Could we prevent Alzheimer's disease by treating herpes?

Survey results highlight the need for better communication between patients and HCPs about bacterial vaginosis

Researchers develop new techniques for faster detection of Lyme disease bacteria

Virginia Tech researcher receives $1.7 million to study herpes simplex virus

Researchers develop cancer vaccine platform to improve efficacy of oncolytic enveloped viruses

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News